

500 Chipeta Way, Salt Lake City, Utah 84108-1221

phone: 801-583-2787, toll free: 800-522-2787

Tracy I. George, MD, Chief Medical Officer

Patient Age/Sex:

Female

Specimen Collected: 15-Jun-22 13:51**Chimerism, Post-Transplant, B cells** | **Received: 15-Jun-22 13:51** | **Report/Verified: 15-Jun-22 15:06**

| Procedure | Result | Units | Reference Interval |
|--|--------|-------|--------------------|
| Chimerism Post-B cell, Whole Blood Specimen | | | |
| Chimerism Post-B cell, 5 InformativeLoc | | | |
| Chimerism Post-B cell, 100 Percent Recip | | % | |
| Chimerism Post-B cell, 0 Percent Donor | | % | |
| Chimerism Post-B cell, Not Applicable Margin Error | | | |
| Chimerism Post-B cell, Type Recipient * f1 i1 | | | |
| Interpretation | | | |

Result Footnote

f1: Chimerism Post-B cell, Interpretation

Section 79-1 of New York State Civil Rights Law requires informed consent be obtained from patients (or their legal guardians) prior to pursuing genetic testing. These forms must be kept on file by the ordering physician. Consent forms for genetic testing are available at www.aruplab.com. Incidental findings are not reported unless clinically significant but are available upon request.

The B cell content of the isolated fraction typically ranges from 86.9 - 98.1%

This result has been reviewed and approved by [REDACTED]

Test Information

i1: Chimerism Post-B cell, Interpretation

BACKGROUND INFORMATION: Chimerism, Posttransplant, Sorted Cells (B Cells)

INDICATION: Monitoring for bone marrow transplant patients; correlation with clinical status and consideration of the interval between bone marrow transplantation and testing is necessary for proper interpretation of results.

METHODOLOGY: PCR followed by capillary electrophoresis. Specimens are analyzed using 15 autosomal markers (D8S1179, D21S11, D7S820, CSF1PO, D3S1358, TH01, D13S317, D16S539, D2S1338, D19S433, vWa, TPOX, D18S51, D5S818, and FGA) and one gender marker (amelogenin).

LIMIT OF DETECTION: 2 percent of minor cell population.

LIMITATIONS: Diagnostic errors can occur due to rare sequence variations.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Tracy I. George, MD

ARUP Accession: 22-166-900130

Report Request ID: 16270572

Printed: 21-Jun-22 07:22

Page 1 of 2

Test Information

i1: Chimerism Post-B cell, Interpretation
Administration. This test was performed in a CLIA-certified laboratory and is
intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Tracy I. George, MD

ARUP Accession: 22-166-900130

Report Request ID: 16270572

Printed: 21-Jun-22 07:22

Page 2 of 2